Highlights
-
Live Today: Are Culture-Expanded Stem Cells Crossing the Line? Join Us Live for the Debate.
Add to your calendar and tune in at 5PM PST
- Today’s Research Article: PRP Beats Splints in CTS Relief — One Injection, Six Months of Gains.
- Questions from the Field: Adipose for the Win: Cushioning Meniscus Tears with Precision.
- Let’s Get Down to Business: From Burnout to Breakthrough — The Healing Power of Mentorship.
- Come Join Us: Level Up Your Skills at Orthosono 2025 in Las Vegas.
If this newsletter was forwarded to you and you'd like to receive future updates directly, subscribe here.
Today’s Research Article
Six-month efficacy of platelet-rich plasma for carpal tunnel syndrome: A prospective randomized, single-blind controlled trial
Yung-Tsan Wu, Tsung-Yen Ho, Yu-Ching Chou, Ming-Jen Ke, Tsung-Ying Li, Guo-Shu, Huang & Liang-Cheng Chen
Summary:
This prospective, randomized, single-blind controlled trial evaluated the 6-month effectiveness of a single ultrasound-guided platelet-rich plasma (PRP) injection in 60 patients with mild-to-moderate carpal tunnel syndrome (CTS). Compared to the control group using night splints, the PRP group experienced significantly greater improvements in pain (VAS scores), functional ability (Boston Carpal Tunnel Questionnaire), and reduced swelling of the median nerve (CSA). The benefits became more pronounced over time, with no adverse effects reported, supporting PRP as a safe and effective non-surgical option for CTS.
Although both groups showed improvements, PRP outperformed splinting across multiple outcomes by the 6-month mark. While electrophysiological changes were similar between groups, PRP showed greater functional and symptomatic relief, likely due to its regenerative, anti-inflammatory, and space-releasing effects. The study highlights PRP’s potential as a valuable alternative for patients not ready or eligible for surgery.
Doctor-to-Patient Talking Points on Why to Choose PRP (Based on the Study):
